A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

Actas Espanolas de Psiquiatria

Volumn 41, Issue 3, 2013, Pages 164-174

  Carrasco, José L ^a   Alvarez, Enrique ^b   Olivares, José M ^c   Rejas, Javier ^d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d PFIZER INC   (United States)

Author keywords

Benzodiazepineresistant patients; Comparative cost analysis; Generalized anxiety disorder; Pregabalin; SSRI SNRI

Indexed keywords

4 AMINOBUTYRIC ACID; ADRENERGIC RECEPTOR AFFECTING AGENT; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; DRUG RESISTANCE; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SPAIN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANXIETY DISORDERS; BENZODIAZEPINES; DRUG RESISTANCE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SPAIN;

EID: 84881288275     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004:21-7.
2. Ansseau M, Fischler B, Dierick M, Mignon A, Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry. 2005;20:229-35.
3. Wetherell JL, Birchler GD, Ramsdell J, Unützer J. Screening for generalizated anxiety disorder in geriatric primary care patients. Int J Geriatr Psychiatry. 2007;22:115-23.
4. Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, et al. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeD-España. Med Clin (Bar). 2006;126:445-51.
5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
6. Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord. 2009;114:14-31.
7. Hoffman D L, Dukes E M, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25:72-90.
8. Kertz SJ, Woodruff-Borden J. Human and Economic Burden of GAD, Subthreshold GAD, and Worry in a Primary Care Sample. J Clin Psychol Med Settings. 2011;18:281-90.
9. Sicras-Mainar A, Blanca-Tamayo M, Navarro-Artieda R, Rejas- Gutiérrez J. Use of resources and costs profile in patients with fibromyalgia or generalized anxiety disorder in primary care settings. Aten Primaria. 2009;41:77-84.
10. Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Beahv Ther. 1997;28:285-305.
11. Martin J L T, Sainz-Pardo M, Furukawa TA, Martín-Sánchez E, Seoane T, Galán C. Benzodiazepines in generalizated anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trial. J Psychopharmacol. 2001;21:774-82.
12. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Arch Gen Psychiatr. 1988;45:444-50.
13. Tyrer P, Owen R, Dawiling S. Gradual withdrawal of diazepam after long-term therapy. Lancet. 1983;34:385-94.
14. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalizated anxiety disorder. Int J Neuropsychopharmacol. 2005;8:293-302.
15. Guideline Working Group for the treatment of Patients with Anxiety Disorders in Primary Care. Madrid: National Plan for the NHS of the MSC. Health Technology Assessment Unit. Lain Entralgo Agency. Community of Madrid; 2008; Clinical Practice Guidelines in the NHS. UETS No 2006/10.
16. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9:248-312.
17. Keck PE, Strawn JR, McElroy SL. Pharmacologic treatment considerations in co-occuring bipolar and anxiety disorders. J Clin Psychiatry. 2006;67:8-15.
18. McElroy SL, Altshuler LL, Suppes T, Keck PE Jr, Frye MA, Denicoff KD, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 outpatients with bipolar disorder. Am J Psychiatry. 2004;158:420-6.
19. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004;161:2222-9.
20. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebocontrolled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-9.
21. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022-30.
22. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, doubleblind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771-82.
23. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebocontrolled trial. Am J Psychiatry. 2003;160:533-40.
24. Simes J. Clinical trials and "real-world" medicine. Med J Aust. 2002;177:407-8.
25. Álvarez E, Carrasco JL, Olivares JM, Vilardaga I, López-Gómez V, Pérez M. Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN Study. Clin Pract Epidemiol Men Health 2012 [in press].
26. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-5.
27. Lobo A, Chamorro L, Luque A, Dal-Ré R, Badia X, Baró E; Grupo de Validación en Español de Escalas Psicométricas (GVEEP). Validación de las versiones en español de la Montgomery-Asberg Depression Scale y la Hamilton Anxiety Rating Scale para la evaluación de la depresión y de la ansiedad. Med Clin (Bare). 2002;118:493-9.
28. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psycopharmacology Revised 1976. Rockville, MD: National Institute for Mental Health, 1976; p. 218-22.
29. Catálogo del Consejo General de Colegios Farmacéuticos: Base de datos de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos. Año 2009. http://www.portalfarma. com/home.nsf. (Accessed August 2009).
30. Oblikue, 2008. eSALUD. Base de datos de costes sanitarios. In: Social, S. C.d. E.e. E.d.l. S.y. P. (Ed.). SOIKOS, Barcelona.
31. INE. 2008 www.ine.es. (Accessed August 2009).
32. Thompson SG, Barber JA. How should cost data in pragmatic randomized trials analyzed? BMJ. 2000;230:1197-200.
33. Sicras-Mainar A, Blanca-Tamayo M, Navarro-Artieda R, Pizarro-Paixa I, Gómez-Lus Centelles S. Influence of morbidity and the use of health resources in patients who require care for generalised anxiety disorder in the primary health care setting. Aten Primaria. 2008;40:603-10.
34. Rovira J, Albarracin G, Salvador-Carulla L, Rejas J, Sánchez-lriso E, Cabases JM. The Cost of Generalized Anxiety Disorder (GAD) in Primary care Settings: Results of the ANCORA Study. Community Ment Health J 2012. DOI: 10.1007/s10597-012-9503-4.
35. Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11:35-44.
36. Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009;70(Supp 2):25-31.
37. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62(Supp 11):53-8.
38. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-27.
39. Iskedjian M, Walker JH, Bereza BG, Le Melledo JM, Einarson TR. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. Curr Med Res Opin. 2008, 24:1539-48.
40. Issakidis C, Sanderson K, Corry J, Andrews G, Lapsley H. Modelling the population cost-effectiveness of current and evidencebased optimal treatment for anxiety disorders. Psychol Med. 2004;34:19-35.
41. Olfson M, Gameroff M. Generalized anxiety disorder, somatic pain and health care costs. General Hospital Psychiatry. 2007;29:310-6.